

Supplementary Table 2 Individual analyses of *BRAF* and *TERT* mutation status in PTC patients by clinicopathologic characteristics.

Clinical feature	<i>BRAF</i> status				<i>TERT</i> status			
	Mutated (N= 84)	Wild type (N= 57)	OR (95%CI)	P- value ₁	Mutated (N=23)	Wild type (N=118)	OR (95% CI)	P- value ¹
Male gender	16	12	0.88 (0.38-2.04)	0.770	6	22	1.54 (0.54-4.36)	0.413
Mean age (SD)	46.7 (13.0)	44.6 (14.7)	NA	0.396	51.3 (13.2)	44.8 (13.6)	NA	0.044
Diagnosis ≥45y	52	32	1.27 (0.64-2.52)	0.494	15	69	1.33 (0.52-3.38)	0.547
CVPTC Subtype	49	26	1.67 (0.85-3.29)	0.137	16	59	2.29 (0.88-5.96)	0.085
Large tumors	34	20	1.26 (0.62-2.55)	0.527	12	42	2.57 (0.97-6.80)	0.051
Multifocal tumors	34	17	1.62 (0.79-3.33)	0.191	4	47	0.37 (0.12-1.17)	0.080
Bilateral tumors	19	6	2.22 (0.82-6.02)	0.112	3	22	0.73 (0.20-2.74)	0.643
Capsular invasion	24	14	1.24 (0.57-2.72)	0.585	7	31	1.98 (0.68-5.79)	0.205
Vascular invasion	30	17	1.35 (0.64-2.86)	0.426	6	41	1.24 (0.40-3.84)	0.704
LNM	34	12	2.27 (1.03-5.00)	0.040	10	36	2.22 (0.83-5.95)	0.107
ETT	20	14	0.94 (0.42-2.07)	0.871	9	25	3.96 (1.38-11.3)	0.007
Distant Metastasis	4	4	0.66 (0.16-2.76)	0.570	3	5	3.39 (0.75-15.3)	0.095
Stage III-IV ²	30	12	2.03 (0.93-4.43)	0.073	13	29	4.33 (1.68-11.18)	0.001
Cancer-related	2	2	0.65 (0.09-4.79)	1.00	2	2	5.14 (0.69-38.57)	0.138

dead		
------	--	--

Abbreviations: CVPTC: Common variant papillary thyroid cancer; LNM: Lymph node metastasis; ETT: extra-thyroid extension. ¹Statistically significant two-tailed p-values are shown in bold. ²Based on American Joint Committee on Cancer (AJCC) protocol of classification but including two cases diagnosed before 45y with metastasis.